Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
2000
20 years of foundational research
In novel approaches for inflammation and fibrosis
2021
Lead assets and pipeline growth
Foundation of Granite Bio by Versant Ventures and Novartis Venture Fund (NVF), integrated into the Ridgeline Discovery Engine. 30 Million USD Series A Financing
2022
Preclinical Development/CMC
Two Development Candidates achieved.
2023
Series B & CTA submission
70 Million USD Series B Financing, completion of CTA enabling studies and CTA submission.
2024
Phase 1 / 1b